Werewolf Therapeutics, Inc.
HOWL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | 0.00 | 0.05 | -0.04 |
| FCF Yield | -16.80% | -30.93% | -43.48% | -21.84% |
| EV / EBITDA | 0.00 | -0.47 | 0.70 | 0.43 |
| Quality | ||||
| ROIC | 0.00% | -21.59% | -18.55% | -17.96% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 1,973.47% |
| Cash Conversion Ratio | 0.93 | 0.84 | 1.05 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -62.02% | -51.38% |
| Free Cash Flow Growth | 0.05% | 19.97% | -31.81% | -15.32% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 2.54 | 3.36 | 3.95 |
| Interest Coverage | 0.00 | -13.48 | -14.24 | -16.06 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -614.93 | -208.31 | -617.99 |